Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.
Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
On the downside, the US Dollar Index may test the lower boundary of the descending channel at 106.10, followed by the key psychological level of 106.00. A break below this critical support zone could ...
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
This contract has experienced an incredible rally since Jan. 22, however, the forward curve is pointing sharply downwards ...
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...
Continued strong commercial execution of the OGSIVEO launch in the U.S. with fourth quarter and full-year 2024 U.S. net product revenue for OGSIVEO of $61.5 million and $172.0 million, respectively.